At Eclevar MedTech, we often see a gap between approval and adoption. A device may have CE marking, strong technical promise, and a clear intended purpose, yet still struggle to gain real traction in the NHS. Why?
Because adoption is shaped by much more than regulatory access. Surgeon confidence, evidence expectations, procurement pressure, operational complexity, and local business case realities all influence whether a product gets used in practice.
For manufacturers, this matters because delays in adoption are rarely caused by a single issue. More often, they reflect a combination of evidence gaps, service model concerns, economic uncertainty, and implementation risk. Understanding these barriers early can help shape a more effective clinical, PMCF, and market access strategy.
Below are some of the most common reasons why CE marked implants and enabling technologies still struggle to get adopted in the NHS, and what manufacturers can do about them.
Are surgeons holding back because they do not want to be the first?
Trying a new implant is not just a clinical decision. It can feel personal, and sometimes risky.
What if the first few cases do not go smoothly? What if the learning curve shows up as a couple of early revisions? What if that draws attention and triggers questions?
In the UK, outcomes are not hidden. The National Joint Registry describes a formal Accountability and Transparency process, including how potential outliers are identified and escalated. When surgeons know their results are being tracked and compared, it naturally makes them more cautious about switching implants. So when a consultant says they are worried about skewing NJR numbers, it is not a myth. It is a rational response to how transparent the system is.
Support early adoption with a structured evidence plan, like RSA or image-based migration studies with at least two years of follow-up and interim readouts. Early PMCF plays an important role here by generating focused post-market evidence relevant to real clinical use.
Are hospitals implicitly saying prove it for ten years before we consider you?
In the UK, adoption often follows evidence labels rather than marketing brochures.
ODEP explains that it rates the strength of evidence submitted by manufacturers, and that the output is an evidence rating for implant performance. ODEP also states that GIRFT recommends surgeons use at least ODEP 10A rated implants, and notes that many hospitals will only purchase ODEP rated products.
That creates a structural disadvantage for new implants that do not yet have long follow up. So the question becomes: how do you sell a new implant into a system that rewards long follow up, while you still need cases to build that follow up?
Do not wait ten years. Build a staged evidence pathway from day one, combining early imaging, prospective follow up, registry entry, PMCF, and a clear roadmap towards stronger ODEP relevant evidence.
Is procurement the real decision maker?
Even when a surgeon is interested, procurement can decide whether the product ever reaches theatre.
The NJR does not only show outcomes. It also helps hospitals compare implant prices. So when a new implant comes in at a higher cost, that difference is visible straight away. NJR reports such as INFORM and EMBED show that hospitals can look at pricing, usage, and variation in quite a detailed way.
That means a new implant has to win two conversations. One in theatre, and one in procurement.
Bring a value package, not just an implant. Provide a clear cost comparison, operational impact, and a credible explanation of why any extra spend is worth it (clinical outcomes, pathway benefits, or better long-term cost profile).
Is variation being actively squeezed out of the system?
Standardisation is not only a preference. In many places it is a policy direction.
The GIRFT orthopaedics follow up report explicitly discusses reducing variation in practice, including variation in implant related decisions. BOA guidance referencing GIRFT states that variation in implant selection creates scope for savings, and it adds a practical safety point that unfamiliarity with multiple implant systems can increase error.
So even if your implant is clinically sound, the system may still prefer fewer options because it makes theatre safer and procurement simpler.
Do not fight standardisation. Show how the new implant fits within a rationalised portfolio, with limited complexity, clear indications, and a controlled rollout plan.
Is the hidden cost of change the real blocker?
A new implant is not just a new device. It is a new process.
Do you need new trays? Do you need more loan kit movement? Does sterile services capacity become a bottleneck? Does theatre turnaround slow down? Do you create rep dependency during early cases?
The GIRFT and BOA themes around rationalisation align with this. The system is trying to reduce complexity, not add it.
Design the rollout around operational simplicity: fewer trays, dependable logistics, theatre team training, and support that protects list efficiency from the first case.
Is reimbursement misaligned with who pays?
Even if a new implant or robot could save money over time, that does not always help the hospital that has to buy it today.
The NHS may have to pay the extra cost now. But the benefit may only show up later, somewhere else in the system. NHS England does have routes to support faster uptake for some technologies, but only for a limited group. Most implants still need to win approval through a local business case.
So for many CE marked implants, the question is not just, does this work? It is also, who pays now, who benefits later, and can we prove the value clearly enough to justify the spend?
The business case has to go beyond implant price and explain the full picture, including recovery, complications, theatre impact, revision risk, resource use, and where the savings actually appear.
Are companies being judged on support as much as on the implant itself?
For a new company, this can be one of the biggest barriers. People are not only asking, is the implant good? They are also asking, will this company actually support us properly?
Will the kit arrive on time? If something goes wrong, can someone help quickly? Is there proper training for the surgeon and theatre team?
If there is any doubt around that, most hospitals will go back to the company they already know. Trust is built less by the brochure, and more by what happens on the day of surgery.
How Eclevar helps manufacturers move from approval to adoption
At Eclevar MedTech, we support manufacturers in orthopaedics, spine, and robotics by helping turn regulatory approval into an evidence and adoption strategy that works in practice. This includes:
- Clinical evidence planning aligned to adoption barriers
- PMCF strategy and post-market evidence generation
- Registry-aware study design and follow-up planning
- Support for ODEP-relevant evidence pathways
- Health economic and value evidence planning
- Operationally realistic rollout planning
- Cross-functional alignment (clinical, regulatory, commercial)
The goal is not simply to generate more data. It is to generate the right evidence, in the right sequence, to support confidence, procurement, adoption, and long-term value.
Design Your StrategyConclusion
The UK is not anti-innovation. It is risk-managed innovation.
If your market plan assumes CE mark equals adoption, you may be disappointed. The real blockers are outcomes visibility, evidence signalling, procurement benchmarking, standardisation pressure, operational burden, support model credibility, and misaligned financial incentives.
The good news is that these barriers are not random. They can be anticipated, designed for, and reduced with the right clinical, PMCF, and market access strategy. If your device has regulatory approval but adoption is still slow, the issue may not be the technology itself. It may be the evidence, rollout, and value strategy around it.
References
- National Joint Registry, Accountability and Transparency
https://www.njrcentre.org.uk/about-the-njr/njr-accountability-and-transparency/ - ODEP, Rating System
https://www.odep.org.uk/about/rating-system/ - ODEP, Impact of ODEP
https://www.odep.org.uk/about/impact-of-odep/ - National Joint Registry, Implant Procurement and price benchmarking overview
https://www.njrcentre.org.uk/about-the-njr/njr-implant-procurement/ - National Joint Registry, INFORM and EMBED reports
INFORM PDF | EMBED PDF - GIRFT, Orthopaedics follow up report February 2020
GIRFT PDF - British Orthopaedic Association, Professional Guidance to implement GIRFT
BOA Guidance - NHS England, MedTech Funding Mandate policy guidance
NHS England Guidance